Furthermore, limited but interesting findings have confirmed that unlike other m6A‐related genes, IGF2BP3 can be detected in the serum of cancer patients, which reveals that serum IGF2BP3 probably can be used as a diagnostic and prognostic marker in prostate and renal cancers.12, 13. This evidence concerns the gene IGF2BP3 and cancer.